At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 471 enrolled
Drug / intervention
Insulin Lispro Protamine Suspension +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The PERSISTENT Trial: A Prospective Randomized Trial Comparing Insulin Lispro Protamine Suspension to Insulin Glargine in Patients With Type 2 Diabetes on Anti-hyperglycemic Medications
In Brief
A Phase 3 clinical trial evaluating Insulin Lispro Protamine Suspension and Insulin Glargine for Diabetes Mellitus, Type 2. Completed, enrolled 471 participants across 17 sites in 4 countries.
Detailed Summary
The purpose of this study is to examine the effectiveness and safety of insulin lispro protamine suspension (ILPS) as compared to insulin glargine as basal insulin therapy in adults with type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesBrazil, Canada, Puerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
First PostedAug 2007
Primary CompletionOct 2008
TodayJul 2026
First PostedAug 3, 2007
Enrollment StartAug 1, 2007
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 18.9 years ago
Interventions
Insulin Lispro Protamine Suspensiondrug
Patient adjusted dose, once daily (QD) or twice daily (BID), injected subcutaneous (SC) x 24 weeks
Insulin Glarginedrug
Patient adjusted dose, once daily (QD), injected subcutaneous (SC) x 24 weeks